Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amit Singh & Abha Mishra. (2023) Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation. Journal of Biomolecular Structure and Dynamics 41:10, pages 4534-4548.
Read now
Read now
Adriana Petrazzuolo, M. Chiara Maiuri, Laurence Zitvogel, Guido Kroemer & Oliver Kepp. (2022) Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 11:1.
Read now
Read now
Amit Singh, Ravi Saini & Abha Mishra. (2022) Novel allosteric inhibitor to target drug resistance in EGFR mutant: molecular modelling and free energy approach. Molecular Simulation 48:9, pages 801-811.
Read now
Read now
Erika L. Crowley, Novin Nezamololama, Kim Papp & Melinda J. Gooderham. (2020) Abrocitinib for the treatment of atopic dermatitis. Expert Review of Clinical Immunology 16:10, pages 955-962.
Read now
Read now
Novin Nezamololama, Erika L. Crowley, Melinda J. Gooderham & Kim Papp. (2020) Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis. Expert Opinion on Investigational Drugs 29:9, pages 911-917.
Read now
Read now
Articles from other publishers (63)
Ke Xu, Hao Tang, Jie Xiong, Xiaofang Ban, Yuchen Duan & Yingfeng Tu. (2023) Tyrosine kinase inhibitors and atherosclerosis: A close but complicated relationship. European Journal of Pharmacology 954, pages 175869.
Crossref
Crossref
Cheryl London. 2023. Therapeutic Strategies in Veterinary Oncology. Therapeutic Strategies in Veterinary Oncology
111
120
.
Henrik Rönnberg. 2023. Therapeutic Strategies in Veterinary Oncology. Therapeutic Strategies in Veterinary Oncology
89
110
.
Lijuan Shu, Chunfu Du & Yunxia Zuo. (2023) Abnormal phosphorylation of protein tyrosine in neurodegenerative diseases. Journal of Neuropathology & Experimental Neurology.
Crossref
Crossref
Samanta Jerin, Amanda J. Harvey & Annabelle Lewis. (2023) Therapeutic Potential of Protein Tyrosine Kinase 6 in Colorectal Cancer. Cancers 15:14, pages 3703.
Crossref
Crossref
Safaa E. Seif, Zeinab Mahmoud, Wagnat W. Wardakhan, Amr M. Abdou & Rasha A. Hassan. (2023)
Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3‐
d
]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR‐2 inhibition, and down‐regulation of PI3K/AKT/mTOR signaling pathway
. Drug Development Research.
Crossref
Crossref
Juan Sun, Ze‐Yu Fang, Yi‐Nuo Tao, Yi‐Heng Zhang, Yao Zhang, Hai‐Ya Sun, Yang Zhou & Yuan‐Feng Wu. (2023) Design, Synthesis and Antitumor Activity of FAK/PLK1 Dual Inhibitors with Quinazolinone as the Skeleton. Chemistry & Biodiversity 20:4.
Crossref
Crossref
Juan Gao, Jingyi Jian, Zhengjin Jiang & Ann Van Schepdael. (2023) Screening assays for tyrosine kinase inhibitors: A review. Journal of Pharmaceutical and Biomedical Analysis 223, pages 115166.
Crossref
Crossref
Mario F. Muñoz, Sandro Argüelles, Antonio Ayala & Francesco Marotta. 2023. Anti-Aging Pharmacology. Anti-Aging Pharmacology
285
304
.
InnocentMary IfedibaluChukwu Ejiofor, Christabel Chikodili Ekeomodi, Augusta Ukamaka IlecChukwu & Maryann Chinedu Ochiamu. 2023. Targeted Cancer Therapy in Biomedical Engineering. Targeted Cancer Therapy in Biomedical Engineering
325
363
.
Josef Jampilek & Katarina Kralova. (2022) Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy. Pharmaceutics 14:12, pages 2706.
Crossref
Crossref
Manuel Ramos-Casals, Alejandra Flores-Chávez, Pilar Brito-Zerón, Olivier Lambotte & Xavier Mariette. (2022) Immune-related adverse events of cancer immunotherapies targeting kinases. Pharmacology & Therapeutics 237, pages 108250.
Crossref
Crossref
Tapan Behl, Amit Gupta, Aayush Sehgal, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya, Asim Najmi, Saurabh Bhatia & Simona Bungau. (2022) Exploring protein tyrosine phosphatases (PTP) and PTP-1B inhibitors in management of diabetes mellitus. Biomedicine & Pharmacotherapy 153, pages 113405.
Crossref
Crossref
Ashish Shah, Chhagan Patel, Ghanshaym Parmar, Ashish Patel & Manav Jain. (2022) A Concise Review on Tyrosine Kinase Targeted Cancer Therapy. Current Drug Therapy 17:2, pages 96-107.
Crossref
Crossref
Amirhosein Maharati, Amir Sadra Zanguei, Ghazaleh Khalili-Tanha & Meysam Moghbeli. (2022) MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells. Cell Communication and Signaling 20:1.
Crossref
Crossref
Rajeev K. Singla, Sahar Behzad, Johra Khan, Christos Tsagkaris, Rupesh K. Gautam, Rajat Goyal, Hitesh Chopra & Bairong Shen. (2022) Natural Kinase Inhibitors for the Treatment and Management of Endometrial/Uterine Cancer: Preclinical to Clinical Studies. Frontiers in Pharmacology 13.
Crossref
Crossref
Chirasmita Nayak & Sanjeev Kumar Singh. 2022. Protein Kinase Inhibitors. Protein Kinase Inhibitors
71
96
.
Sampreeti Jena & Laurie L. Parker. 2022. Biomedical Engineering Technologies. Biomedical Engineering Technologies
133
162
.
Jie Zhang, Weidong Liu, Sisi Feng & Baiyun Zhong. (2021) The possible role of SRMS in colorectal cancer by bioinformatics analysis. World Journal of Surgical Oncology 19:1.
Crossref
Crossref
M.N. Ferrao Blanco, H. Domenech Garcia, L. Legeai-Mallet & G.J.V.M. van Osch. (2021) Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis. Osteoarthritis and Cartilage 29:10, pages 1389-1398.
Crossref
Crossref
Omer Bayazeid & Taufiq Rahman. (2021) Correlation Analysis of Target Selectivity and Side Effects of FDA‐Approved Kinase Inhibitors**. ChemistrySelect 6:30, pages 7799-7814.
Crossref
Crossref
Kaijuan Wu, Xingyu Zhai, Shuaiqin Huang, Liping Jiang, Zheng Yu & Jing Huang. (2021) Protein Kinases: Potential Drug Targets Against Schistosoma japonicum. Frontiers in Cellular and Infection Microbiology 11.
Crossref
Crossref
Sevgi Uğur MUTLUAY & Leyla Didem KOZACI. (2021) Hücre İçi Sinyal Yolaklarını Hedefleyen Kemoterapötik AjanlarChemotherapeutic Agents Targeting Intracellular Signaling Pathways. Black Sea Journal of Health Science 4:2, pages 175-184.
Crossref
Crossref
Fabian A. Mendoza, Sonsoles Piera-Velazquez & Sergio A. Jimenez. (2021) Tyrosine kinases in the pathogenesis of tissue fibrosis in systemic sclerosis and potential therapeutic role of their inhibition. Translational Research 231, pages 139-158.
Crossref
Crossref
Sanjoy Das, Bireswar Bhattacharya, Biplajit Das, Bibek Sinha, Taison Jamatia & Kishan Paul. (2019) Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies. Indian Journal of Surgical Oncology 12:S1, pages 34-45.
Crossref
Crossref
Anna Choromańska, Agnieszka Chwiłkowska, Julita Kulbacka, Dagmara Baczyńska, Nina Rembiałkowska, Anna Szewczyk, Olga Michel, Agnieszka Gajewska-Naryniecka, Dawid Przystupski & Jolanta Saczko. (2021) Modifications of Plasma Membrane Organization in Cancer Cells for Targeted Therapy. Molecules 26:7, pages 1850.
Crossref
Crossref
Ting Guo & Shutao Ma. (2020) Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. ChemMedChem 16:4, pages 600-620.
Crossref
Crossref
Zhiyi Zhang, Jie Song, Cao Xie, Jun Pan, Weiyue Lu & Min Liu. (2021) Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials. The AAPS Journal 23:2.
Crossref
Crossref
. 2021. Goodman's Medical Cell Biology. Goodman's Medical Cell Biology
271
294
.
Elvira Hermawati, Suzany D. Ellita, Lia D. Juliawaty, Euis H. Hakim, Yana M. Syah & Hayato Ishikawa. (2020) Epoxyquinophomopsins A and B from endophytic fungus Phomopsis sp. and their activity against tyrosine kinase. Journal of Natural Medicines 75:1, pages 217-222.
Crossref
Crossref
Sunil Kumar, Abhishek Kumar Sharma, H. Lalhlenmawia & Deepak Kumar. 2021. Targeting Cellular Signalling Pathways in Lung Diseases. Targeting Cellular Signalling Pathways in Lung Diseases
821
846
.
Xiang Xiao, Dongwang Zheng, Fei Liang, Shibo Ying, Peibei Sun, Jianmin Yu & Ya Ni. 2021. Molecular Mechanisms in Spermatogenesis. Molecular Mechanisms in Spermatogenesis
1
20
.
Ning Ma, Hengjun Du, Gaoxing Ma, Wenjian Yang, Yanhui Han, Qiuhui Hu & Hang Xiao. (2020)
Characterization of the Immunomodulatory Mechanism of a
Pleurotus eryngii
Protein by Isobaric Tags for Relative and Absolute Quantitation Proteomics
. Journal of Agricultural and Food Chemistry 68:46, pages 13189-13199.
Crossref
Crossref
Andrea Baier & Ryszard Szyszka. (2020) Compounds from Natural Sources as Protein Kinase Inhibitors. Biomolecules 10:11, pages 1546.
Crossref
Crossref
Marc Hoemberger, Warintra Pitsawong & Dorothee Kern. (2020) Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proceedings of the National Academy of Sciences 117:32, pages 19221-19227.
Crossref
Crossref
Atieh Yaghoubi, Majid Khazaei, Amir Avan, Seyed Mahdi Hasanian, William C. Cho & Saman Soleimanpour. (2020) p28 Bacterial Peptide, as an Anticancer Agent. Frontiers in Oncology 10.
Crossref
Crossref
Paolo Pisani, Mario Airoldi, Anastasia Allais, Paolo Aluffi Valletti, Mariapina Battista, Marco Benazzo, Roberto Briatore, Salvatore Cacciola, Salvatore Cocuzza, Andrea Colombo, Bice Conti, Alberto Costanzo, Laura della Vecchia, Nerina Denaro, Cesare Fantozzi, Danilo Galizia, Massimiliano Garzaro, Ida Genta, Gabriela Alejandra Iasi, Marco Krengli, Vincenzo Landolfo, Giovanni Vittorio Lanza, Mauro Magnano, Maurizio Mancuso, Roberto Maroldi, Laura Masini, Marco Carlo Merlano, Marco Piemonte, Silvia Pisani, Adriele Prina-Mello, Luca Prioglio, Maria Gabriella Rugiu, Felice Scasso, Agostino Serra, Guido Valente, Micol Zannetti & Angelo Zigliani. (2020) Metastatic disease in head & neck oncologyLa malattia metastatica in oncologia testa-collo. Acta Otorhinolaryngologica Italica 40:SUPPL. 1, pages S1-S86.
Crossref
Crossref
Dakota Gustafson, Jason E. Fish, Jeffrey H. Lipton & Nazanin Aghel. (2020) Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Current Hematologic Malignancy Reports 15:1, pages 20-30.
Crossref
Crossref
Hermes Vieira Barbeiro, Denise Frediani Barbeiro & Francisco Garcia Soriano. 2020. Precision Medicine for Investigators, Practitioners and Providers. Precision Medicine for Investigators, Practitioners and Providers
281
289
.
Sabrina Solouki, Avery August & Weishan Huang. (2019) Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications. Pharmacology & Therapeutics 201, pages 39-50.
Crossref
Crossref
Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv & Jiajie Luan. (2019) Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets 20:11, pages 1180-1202.
Crossref
Crossref
Debarshi Banerjee, Artur Cieslar-Pobuda, Geyunjian Harry Zhu, Emilia Wiechec & Hirak K. Patra. (2019) Adding Nanotechnology to the Metastasis Treatment Arsenal. Trends in Pharmacological Sciences 40:6, pages 403-418.
Crossref
Crossref
Dong Hyun Jo, Jin Hyoung Kim & Jeong Hun Kim. (2018) Targeting tyrosine kinases for treatment of ocular tumors. Archives of Pharmacal Research 42:4, pages 305-318.
Crossref
Crossref
Bochuan Li, Jinlong He, Huizhen Lv, Yajin Liu, Xue Lv, Chenghu Zhang, Yi Zhu & Ding Ai. (2019) c-Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow. Journal of Clinical Investigation 129:3, pages 1167-1179.
Crossref
Crossref
Chenbo Ding, Wendong Tang, Hailu Wu, Xiaobo Fan, Junmin Luo, Jihong Feng, Kunming Wen & Guoqiu Wu. (2019) The PEAK1–PPP1R12B axis inhibits tumor growth and metastasis by regulating Grb2/PI3K/Akt signalling in colorectal cancer. Cancer Letters 442, pages 383-395.
Crossref
Crossref
Luca Sala, Giovanni Cirillo, Gabriele Riva, Gabriele Romano, Carlo Giussani, Annamaria Cialdella, Antonio Todisco, Assunta Virtuoso, Maria Grazia Cerrito, Angela Bentivegna, Emanuela Grassilli, Antonio Ardizzoia, Emanuela Bonoldi, Roberto Giovannoni, Michele Papa & Marialuisa Lavitrano. (2019) Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype. Frontiers in Molecular Neuroscience 12.
Crossref
Crossref
Monica Kruk, Naomi Widstrom, Sampreeti Jena, Nicole L. Wolter, John F. Blankenhorn, Ibrahim Abdalla, Tzu-Yi Yang & Laurie L. Parker. 2019. Post-translational Modifications That Modulate Enzyme Activity. Post-translational Modifications That Modulate Enzyme Activity
375
406
.
Qinlian Jiao, Lei Bi, Yidan Ren, Shuliang Song, Qin Wang & Yun-shan Wang. (2018) Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Molecular Cancer 17:1.
Crossref
Crossref
Victor Pallarès, Montserrat Hoyos, M. Chillón, Eva Barragán, M. Prieto Conde, Marta Llop, Aïda Falgàs, María Céspedes, Pau Montesinos, Josep Nomdedeu, Salut Brunet, Miguel Sanz, Marcos González-Díaz, Jorge Sierra, Ramon Mangues & Isolda Casanova. (2018) Focal Adhesion Genes Refine the Intermediate-Risk Cytogenetic Classification of Acute Myeloid Leukemia. Cancers 10:11, pages 436.
Crossref
Crossref
Miroslav Průcha, Roman Zazula & Stefan Russwurm. (2018) Sepsis Diagnostics in the Era of “Omics” Technologies. Prague Medical Report 119:1, pages 9-29.
Crossref
Crossref
L. V. K. S. Bhaskar & L. Saikrishna. 2018. Role of Tyrosine Kinases in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies
191
224
.
Meng Gao, Jingjing Zhou, Zhengding Su & Yongqi Huang. (2017) Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy. Protein Science 26:12, pages 2334-2341.
Crossref
Crossref
Xīn Gào & Ben Schöttker. (2017) Reduction-oxidation pathways involved in cancer development: a systematic review of literature reviews. Oncotarget 8:31, pages 51888-51906.
Crossref
Crossref
Evan C Lien, Christian C Dibble & Alex Toker. (2017) PI3K signaling in cancer: beyond AKT. Current Opinion in Cell Biology 45, pages 62-71.
Crossref
Crossref
Haoyu Li, Yongfeng Wang, Zhenghu Chen, Jiaxiong Lu, Jessie Pan, Yang Yu, Yanling Zhao, Huiyuan Zhang, Ting Hu, Qing Liu & Jianhua Yang. (2016)
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth
in vivo
. Oncotarget 8:4, pages 5874-5884.
Crossref
Crossref
Terry King-Wing Ma, Stephen P McAdoo & Frederick Wai Keung Tam. (2017) Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. Nephrology Dialysis Transplantation 32:suppl_1, pages i129-i138.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
9
56
.
Rebecca L. BoddickerGina L. Razidlo, Surendra DasariYu ZengGuangzhen HuRyan A. KnudsonPatricia T. GreippJaime I. DavilaSarah H. JohnsonJulie C. PorcherJames B. SmadbeckBruce W. EckloffDaniel D. Billadeau, Paul J. KurtinMark A. McNiven, Brian K. LinkStephen M. Ansell, James R. Cerhan, Yan W. Asmann, George VasmatzisAndrew L. Feldman. (2016) Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. Blood 128:9, pages 1234-1245.
Crossref
Crossref
Helena G. Dos Santos & Jessica Siltberg-Liberles. (2016) Paralog-Specific Patterns of Structural Disorder and Phosphorylation in the Vertebrate SH3?SH2?Tyrosine Kinase Protein Family. Genome Biology and Evolution 8:9, pages 2806-2825.
Crossref
Crossref
Yongjun Sun, You Chen, Liying Zhan, Linan Zhang, Jie Hu & Zibin Gao. (2016) The role of non-receptor protein tyrosine kinases in the excitotoxicity induced by the overactivation of NMDA receptors. Reviews in the Neurosciences 27:3, pages 283-289.
Crossref
Crossref
Terry King-Wing Ma, Stephen P. McAdoo & Frederick Wai-Keung Tam. (2016) Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. Nephron 133:4, pages 261-269.
Crossref
Crossref
Ewa Marcinkowska & Elżbieta Gocek. 2016. Resistance to Tyrosine Kinase Inhibitors. Resistance to Tyrosine Kinase Inhibitors
1
25
.
Kai-Cheng Hsu, Tzu-Ying Sung, Chih-Ta Lin, Yi-Yuan Chiu, John T.-A. Hsu, Hui-Chen Hung, Chung-Ming Sun, Indrajeet Barve, Wen-Liang Chen, Wen-Chien Huang, Chin-Ting Huang, Chun-Hwa Chen & Jinn-Moon Yang. (2015) Anchor-based classification and type-C inhibitors for tyrosine kinases. Scientific Reports 5:1.
Crossref
Crossref